College spin-out company list_
The College continues to focus on the commercialisation of its research. New companies have been created during the past year, and continue to spin out – currently at a rate of two a month.
Acrobot The company has developed a surgical robotic system and software which allows a surgeon to plan operations and control the procedure but with an active constraint system designed to prevent errors. The first applications will be knee and back surgery.
Amedis will develop and apply radical technologies for the improvement of the medicinal properties of drugs. The first programme is in the computational prediction of pharmacokinetics and metabolism of candidate drugs.
Discovery was established in 2000 and is dedicated to the production
of high-quality lead series drug candidates. Argenta scientists work to
develop lead compounds from high-throughput screening, especially in the
fields of asthma, pulmonary disease, diabetes, anti-infectives and obesity.
Argenta Discovery secured £7.2m of venture capital in September
Biogeny (Implyx) Implyx is developing a technology for preparing and purifying relatively large proteins which will be capable of passing across the cell membrane to deliver drugs directly to individual cells. Applications include therapy for genetic disease, cancer treatment and the development of antibacterial and antiviral approaches. Implyx is a subsidiary of Biogeny plc which is quoted on the Ofex Stock Exchange.
Casect is developing plasma chips and miniaturised gas chromatography devices for detection of gases and liquids in biological and environmental applications.
Circassia The company’s lead product is directed at the treatment of allergy to the domestic cat, which can have life-threatening consequences. Ongoing research is aimed at generating other products with potential for the treatment of a range of allergies.
com.Medica is dedicated to the development, marketing and distribution of electronic health record software (PiRiLiS) which transforms the efficiency of healthcare organisations and provides significant time and cost savings. PiRiLiS, an IP based technology, runs on standard, open-system internet technology within any web browser, is fully standard compliant and integrates with a complete range of existing healthcare systems including imaging.
D-GEN is a company focused on developing screening tests and diagnostics for prion diseases in humans and animals. Subsequent to the outbreak of BSE in the UK there has been a heightened awareness of prion diseases. Specifically, concern over a potential epidemic of vCJD (human prion disease) has led to the urgent need for rapid, sensitive and specific tissue and blood-based diagnostic tests.
DeltaDOT & Diamond Optical Technology Diamond Optical Technologies Ltd possess a broad spectrum of IPR in imaging and other advanced technologies. Their large biotechnology portfolio is being developed through deltaDOT Ltd. deltaDOT uses inherently digital, Label Free Intrinsic Imaging (LFII) in a wide range of biotechnology arenas including genomics, transcriptomics and proteomics.
Encodica is developing technology related to microtagging for use in the fields of combinatorial chemistry and genomics. The technology facilitates the construction of large particle-based arrays (each particle being uniquely identifiable by a binary code) at a reduced cost to the manufacturer.
Gene Expression Technologies is a functional genomics company, established to commercialise the Gene ICETM technology for the specific inactivation of genes by chromatin engineering. The technology has applications in pharmaceutical drug target discovery and validation, and the development of hormone receptor regulation drugs for the next generation of cancer therapies. In the longer term, it will also be of value in the fields of agriculture and human gene therapy.
Geotechnical Observations Established in April 2000, the aim of Geotechnical Observations is to establish itself as a leader in the provision of high quality geotechnical services based on direct field/laboratory observations. Clients include the Highways Agency, London Underground Limited and UK based insurance and oil companies.
Holoscan is developing a proprietary high speed 3-D imaging technology based on photorefractive holography. Applications include non-invasive imaging through biological tissue, which has the potential to replace biopsy as the standard method of examining potential tumours. Other potential applications range from medical and dental diagnosis to fast 3D image capture for computer animation.
technology is risk management software used to evaluate mining projects
using Discounted Cash Flow techniques in a fraction of the normal time.
The company aims to transfer this technology and expertise into other
sectors and to develop and distribute other complimentary applications
and training, all available through a web browser.
Imperial Compact Carbons Established in August 2000 as a joint venture with Compact Power Limited, Imperial Compact Carbons is working to develop technology for the conversion of waste materials, which is then itself used in a variety of applications, including treatment of gaseous and acqueous effluents.
provides a platform for the analysis of large-scale scientific data across
the Internet/intranet, supporting interactive and incremental discovery
and global collaborative research. By applying novel technologies, including
scaleable data mining, Internet-based dynamic data integration and knowledge
management and advanced interactive visual analysis, InforSense provides
the world’s first fully functional e-science environment and will first
target the fields of drug discovery and genomics.
Materials Processing IMP has developed a revolutionary materials coating
technology which allows rapid, flexible and cost-effective coating. The
technology has the potential to replace expensive, time consuming and
unwieldy methods and can be applied in a wide range of fields including
bio-coatings, fuel cell materials and catalysts.
Integration Diagnostics aim to develop hand-held diagnostic equipment for testing the success of dental implants.
IC Innovations assisted the London School of Pharmacy in the formation
of Lipoxen Ltd, under its contract for provision of commercial services
to the School. The company is focused on novel developments in liposome
is focused on an understanding of basic mechanisms of immune regulation.
The technology has potential for therapeutic applications in a range of
immune-related conditions, auto-immune diseases and transplantation.
Extraction Technologies apply membrane technology to selectively separate
out specific components of process streams, thereby allowing cleaner manufacture,
recovery of valuable chemicals, and treatment of waste streams. MET works
with customers to provide process-integrated solutions which are installed
and operated by MET on the customer site.
MerTeK is developing extreme ultra violet light sources for lithography and other laser light applications for sale to the engineering and semiconductor industries.
Metabometrix has developed methods for biological sample analysis using nuclear magnetic resonance technology for use in the pharmaceutical and biotechnology industries.
focuses on the development of vaccines for infectious disease, in particular
the identification and production of vaccines against Group B Streptococcus
in pregnancy/new-borns. The company is also working to determine genes
critical to virulence (ability to cause disease) in bacteria.
OrbB is creating products and services in healthcare delivery that parallel the flight recorders (black box) and flight simulators of the airline industry – ‘virtual operating theatres’.
Logic has developed a collaborative e-commerce platform, StarActive.
The platform enables businesses to create their own private collaborative
commerce solutions for B2B networks, offering new methods to sell more
products and services, cut inventories, minimise waste in materials and
achieve significant cost savings.
Technologies develops and supplies state-of-the-art software applications
for decision support, strategic planning and resource optimisation. Its
products solve problems of a scale and complexity beyond the reach of
Protein Arrays The company is developing a novel DNA protein array technology for use in drug discovery. The platforms are designed to be extremely flexible and exploit the power of protein engineering tools coupled to microarray fabrication and fluorescence imaging technology.
has developed an informatics strategy for examining and large scale (genome
wide) mining of sequence databases in order to identify and optimize peptide
structure capable of interacting with and altering the functionality of
Protexeon The company is investigating the use of xenon as an anaesthetic and a neuroprotectant with potential applications in the treatment of, amongst other indications, stroke.
Systems Enterprise PSE provides advanced software and services for
modelling, simulation and optimisation of plants and operations in the
process industries. These technologies address pressing needs in fast
growing engineering and automation market segments of the food, chemicals,
fine chemicals, pharmaceuticals and biotech industries.
Sterix became operational in 1998 taking assignment of a portfolio of IP originating from the College and the University of Bath. In that year the company entered into a multi-million pound licence agreement with a major European pharmaceutical company in the area of female hormone replacement therapy and oral contraception. The company currently has three additional products in development directed towards cancer and a pipeline of projects in discovery.
Bayley has developed software supporting e-purchasing, particularly
for high volume/low cost supplies so that purchasing requirements can
be devolved directly to many individuals within an organisation, offering
a number of benefits in efficiency, ease of management and cost to both
the organisation, suppliers and users.
Toumaz Technology was formed to exploit expertise in developing a mobile phone that works on both digital and analogue networks. In addition, the company aims to design electronic chips using analogue techniques that will reduce the power consumption of small wireless devices.
Genset was established in 1993 to exploit technology related to small-scale
electricity generation using high speed motor/generators in combination
with turbomachinery. The technology enables high speed electrical generators
to run on any fuel, and generate heat and light in remote or in aerospace
applications. The company acquired a listing on the UK London Techmark
exchange in July 2000.